Merck & Co. said sales of their Keytruda cancer immunotherapy exceeded $1 billion for the first time, but the cost of a cyber attack that temporarily crippled manufacturing and declines in off-patent products caused overall revenue to fall.
5/5
5-stars!
Jeffrey P
